Siren Biotechnology is a biotech company focused on developing innovative cancer treatments through a unique gene therapy platform. The company merges two advanced therapeutic technologies: adeno-associated virus (AAV) gene therapy and cytokine immunotherapy. This integrated approach addresses significant challenges in cancer treatment, including drug delivery, efficacy, and toxicity. By combining these methods, Siren Biotechnology aims to enhance the elimination of tumor cells and stimulate anti-tumor immune responses, offering a novel strategy for combating cancer.
Wyndly is dedicated to providing lifelong relief for individuals suffering from environmental allergies, addressing the needs of approximately 60 million Americans. The company specializes in personalized allergy treatment therapies, offering a tailored approach that goes beyond traditional antihistamines and nasal sprays. Wyndly's clinically proven immunotherapy drops target the underlying causes of allergies, delivering effective long-term solutions. By combining these therapies with exceptional online care, Wyndly makes allergy treatment both accessible and affordable, ensuring that patients can achieve a more comfortable, allergy-free life.
Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.
Kernal Biologics, Inc. specializes in the design and development of mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company utilizes its mRNA platform to assist researchers and organizations in creating vaccines and therapeutics. Kernal's innovative therapies instruct specific cells to produce their own therapeutic agents, thereby enhancing treatment efficacy. The company has garnered recognition for its work, receiving multiple awards from notable institutions, including Amgen and NASA. With a foundation rooted in research from MIT and Harvard, the team at Kernal Biologics possesses extensive expertise in the mRNA field, building on their prior successes in the biotechnology sector.
BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.
Omada Health, Inc. is a digital healthcare company that creates online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health helps employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the needs of participants, including services for diabetes prevention and management, hypertension, behavioral health, and musculoskeletal issues. By integrating professional health coaching, connected devices, real-time data, and personalized feedback, Omada Health strives to empower individuals to engage with their health and achieve sustainable lifestyle changes. It is recognized as the largest provider of the National Diabetes Prevention Program by the CDC.
DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes (fungi, bacteria, viruses, etc.).
The company was founded in 2017 and is headquartered in Boston, Massachusetts with a satellite office in Emeryville, California.
Klivo is a health technology company that operates a patient management platform designed to support individuals with chronic conditions in leading healthier lives. The platform enables real-time monitoring of health conditions and facilitates the transmission of blood glucose data. Additionally, it provides users with answers to questions related to clinical conditions, nutrition, and other relevant topics. By equipping healthcare professionals with essential data and insights, Klivo aims to enhance clinical outcomes for patients managing chronic illnesses.
Teiko.bio is an immune profiling platform founded in 2020 and based in Salt Lake City, Utah. The company focuses on delivering insights that assist clinicians in making informed decisions regarding patient responses to therapies. Its platform analyzes immune features linked to treatment responses, identifies rational targets for potential combination therapies, and evaluates the abundance and activation levels of various immune cell types. By providing this comprehensive immune profiling, Teiko.bio aims to enhance patient outcomes and facilitate new discoveries in therapeutic pathways.
OxCan is a startup focused on early lung cancer detection using machine learning and liquid biopsy techniques. The company has developed an artificial intelligence-based healthcare platform that identifies cancer through targeted blood testing. This platform effectively detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine analysis. It evaluates multidimensional liquid biopsy results, including DNA, proteins, epigenetic factors, as well as incorporating epidemiological data and patient medical histories. By providing healthcare providers with the tools for early cancer detection, OxCan aims to facilitate timely and potentially curative treatment options.
Developer of neurological disorders therapy designed for critical mediators of inhibition within the brain. The company's platform has developed a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine to improve the lives of people suffering from neurological disorders by fine-tuning inhibition to treat conditions such as epilepsy, pain, and other central nervous system pathologies, thereby enabling the healthcare industry to resist neurodegeneration, restore excitation, and regenerate neurons.
Operator of a biotechnology platform intended to increase binding affinity and improve consistency to help create personalized, precision cancer vaccines for patients of all backgrounds. The company's platform focuses on developing a single-molecule, massively parallel, de novo next-generation protein sequencing platform, enabling scientists and researchers to develop novel therapeutics and diagnostics and ultimately understand human biology and disease.
Developer of a novel diagnosis technology designed to detect cancers earlier from a simple blood sample. The company's technology uses the biological features that make each cancer type and each individual person's cancer unique by focusing on the things that differentiate a cancer cell from a healthy cell, enabling healthcare professionals to conduct diagnoses of early smaller tumors and apply personalized and effective cancer treatment strategies for patients.
Developer of a birth control optimization test designed to help determine which method of birth control is the best fit for anybody in order to minimize side effects. The company provides medically actionable scientific insights to find the right type of birth control, enabling women to proactively optimize their health-from birth control to fertility, and beyond.
uLab Systems Inc. is a developer of innovative software technology designed for digital dental treatment planning specifically for orthodontists. Founded in 2015 and based in Redwood City, California, with an additional office in Shanghai, China, the company offers a platform that allows orthodontists to create customized treatment plans tailored to individual patient needs. Utilizing proprietary architecture and artificial intelligence, uLab enables practitioners to develop chairside treatment plans in under five minutes, significantly streamlining the process. The technology also facilitates the creation of aligner movement plans and the printing of custom aligners, helping orthodontists manage their treatment plans more efficiently, lower laboratory costs, and expedite the delivery of orthodontic appliances.
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Kit specializes in at-home health and lab testing solutions that enable businesses and organizations to offer a safe and convenient alternative to traditional doctor and laboratory visits. The company's comprehensive testing kits are designed to make preventative health testing accessible across various industries, allowing customers to manage their health from the comfort of their homes. By providing reliable and easy-to-use testing options, Kit aims to enhance the accessibility of health services for individuals and organizations alike.
Kernal Biologics, Inc. specializes in the design and development of mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company utilizes its mRNA platform to assist researchers and organizations in creating vaccines and therapeutics. Kernal's innovative therapies instruct specific cells to produce their own therapeutic agents, thereby enhancing treatment efficacy. The company has garnered recognition for its work, receiving multiple awards from notable institutions, including Amgen and NASA. With a foundation rooted in research from MIT and Harvard, the team at Kernal Biologics possesses extensive expertise in the mRNA field, building on their prior successes in the biotechnology sector.
R-Zero Systems, Inc. is a San Francisco-based company founded in 2020 that specializes in developing hospital-grade disinfection devices aimed at reducing the transmission of pathogens in various environments. The company offers innovative solutions, including the R-Zero Arc, a UV-C disinfection device designed to sanitize both surfaces and air in dynamic spaces such as schools, restaurants, hotels, and other enterprises. R-Zero focuses on biosafety technologies that protect businesses and communities from infectious diseases, leveraging science-backed protocols to enhance cleanliness and safety. Its products are designed for ease of use, allowing cleaning crews to effectively disinfect large areas quickly, thereby mitigating the spread of viruses, including those responsible for COVID-19 and other illnesses.
BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.
Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.
Fluent BioSciences is a privately funded life science company focused on developing high-sensitivity molecular analytical products. Utilizing proprietary instrument-free micro-self-assembly technology, the company enables the analysis of extremely low molecular and cellular sample inputs. Its platform facilitates the instantaneous self-assembly of individual cells or molecules into millions of uniform partitions, allowing for sensitive and unbiased preparation of proteins and nucleic acids for sequencing applications. This innovative approach provides researchers in the biotechnology sector with enhanced capabilities for single-cell analysis, broadening their access to advanced analytical techniques.
Omada Health, Inc. is a digital healthcare company that creates online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health helps employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the needs of participants, including services for diabetes prevention and management, hypertension, behavioral health, and musculoskeletal issues. By integrating professional health coaching, connected devices, real-time data, and personalized feedback, Omada Health strives to empower individuals to engage with their health and achieve sustainable lifestyle changes. It is recognized as the largest provider of the National Diabetes Prevention Program by the CDC.
Gali Health, Inc. is a health technology company based in San Francisco, California, established in 2015. The company focuses on developing a mobile application named Gali, which serves as a personal health assistant designed to support individuals with chronic conditions. By leveraging collective intelligence, Gali enables users to proactively manage their health through crowdsourced personal health data and medically-validated insights. The application employs artificial intelligence to provide highly personalized support, addressing medical, lifestyle, and psychological aspects of living with chronic diseases. Gali Health aims to empower users by ensuring they do not feel isolated or powerless in managing their health, advancing consumer-driven healthcare through innovative technology and personalized health tracking.
DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes (fungi, bacteria, viruses, etc.).
The company was founded in 2017 and is headquartered in Boston, Massachusetts with a satellite office in Emeryville, California.
Pillo, Inc. designs and develops a digital care management platform that provides health care plans for adults with chronic conditions at home. The company offers Pillo, a robot, which enable people to manage their health; answer health and wellness questions; connect with healthcare professionals; manage vitamins and medication; and store, dispense, and order refills when required. The company’s robot also sends notifications to the user when medications are missed; sees and hears user to keep them healthy and safe; and syncs with wearables and smart home devices. Pillo, Inc. was incorporated in 2015 and is based in New York, New York.
Wild Earth is a technology startup based in Berkeley, California, founded in 2017. The company focuses on developing high-protein pet foods that prioritize health, environmental sustainability, and humane sourcing compared to traditional pet food products. By leveraging scientific advancements, Wild Earth aims to reinvent pet nutrition and create cleaner, more nutritious options for pet owners and their animals.
BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.
Qulab Inc. develops systems to automate drug designing. The company was founded in 2017 and is headquartered in Los Angeles, California.
uLab Systems Inc. is a developer of innovative software technology designed for digital dental treatment planning specifically for orthodontists. Founded in 2015 and based in Redwood City, California, with an additional office in Shanghai, China, the company offers a platform that allows orthodontists to create customized treatment plans tailored to individual patient needs. Utilizing proprietary architecture and artificial intelligence, uLab enables practitioners to develop chairside treatment plans in under five minutes, significantly streamlining the process. The technology also facilitates the creation of aligner movement plans and the printing of custom aligners, helping orthodontists manage their treatment plans more efficiently, lower laboratory costs, and expedite the delivery of orthodontic appliances.
Curai is a virtual care company that leverages artificial intelligence to provide chat-based primary care services at reduced costs. Founded in 2017 by Neal Khosla and Xavier Amatriain, the company is headquartered in Palo Alto and aims to make high-quality, affordable primary care accessible globally. Curai's platform combines the expertise of clinicians with advanced AI technologies, facilitating a learning healthcare system that enhances the efficiency and effectiveness of care delivery. By helping patients communicate relevant information to medical professionals, Curai enables more accurate diagnoses and fosters improved patient outcomes. The service is available to individuals directly or through partnerships with enterprises.
Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.
Alveo Technologies, Inc. develops innovative diagnostic devices for infectious diseases, headquartered in Alameda, California. Established in 2014, the company offers a system called be.well, which includes nasal swabs, disposable cartridges, a handheld analyzer, and a cloud-based diagnostics platform. This platform integrates sample preparation, genetic material amplification, and real-time detection to identify various illnesses, including Flu A/B, COVID-19, and RSV. By leveraging advances in sensing, microfluidics, and bioassays, Alveo Technologies aims to empower consumers, healthcare professionals, and treatment providers with timely and accurate diagnostic information, facilitating faster and more informed healthcare decisions.
Singular Bio, Inc. is a San Francisco-based company founded in 2012 that specializes in diagnostic testing for personalized medicine. The company has developed a cutting-edge technology for single molecule analysis of DNA, which offers exceptional sensitivity in detecting various common health conditions. Singular Bio's proprietary detection system aims to address the needs of high-volume healthcare testing, combining the accuracy of genetic analysis with the affordability and rapid results typically associated with screening tests. By leveraging advanced optics alongside custom molecular biology and chemistry, Singular Bio seeks to enhance healthcare accessibility and enable early detection of medical conditions for a broader population. As of mid-2019, Singular Bio operates as a subsidiary of Invitae Corporation.
Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics' technology leverages massive gains in print speed and resolution to break the microvasculature barrier.
uLab Systems Inc. is a developer of innovative software technology designed for digital dental treatment planning specifically for orthodontists. Founded in 2015 and based in Redwood City, California, with an additional office in Shanghai, China, the company offers a platform that allows orthodontists to create customized treatment plans tailored to individual patient needs. Utilizing proprietary architecture and artificial intelligence, uLab enables practitioners to develop chairside treatment plans in under five minutes, significantly streamlining the process. The technology also facilitates the creation of aligner movement plans and the printing of custom aligners, helping orthodontists manage their treatment plans more efficiently, lower laboratory costs, and expedite the delivery of orthodontic appliances.
Manus Bio Inc. recreates plant processes in microorganisms to produce natural ingredients through fermentation. The company’s microbial platform converts sugar sources into ingredients with applications, such as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. It merges metabolic engineering, protein engineering, and systems biology technologies to generate microbes that produce various plant-based ingredients. The company has a strategic partnership with BBGI Public Company Limited. Manus Bio Inc. was formerly known as Manus Biosynthesis, Inc. and changed its name to Manus Bio Inc. in June 2018. The company was founded in 2011 and is based in Cambridge, Massachusetts. It has manufacturing facilities in Cambridge, Massachusetts; and Augusta, Georgia.
Omada Health, Inc. is a digital healthcare company that creates online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health helps employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the needs of participants, including services for diabetes prevention and management, hypertension, behavioral health, and musculoskeletal issues. By integrating professional health coaching, connected devices, real-time data, and personalized feedback, Omada Health strives to empower individuals to engage with their health and achieve sustainable lifestyle changes. It is recognized as the largest provider of the National Diabetes Prevention Program by the CDC.
Lemonaid Health focuses on changing the patient experience and improving and optimizing clinical care through the advancements in machine learning and AI. It leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumers for less than typical co-pays. It was founded in 2013 and is headquartered in San Francisco, California.
Rocket Pharmaceuticals is an emerging biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. The Company’s lead program is a lentiviral-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-1 (LAD-1) and Infantile Malignant Osteopetrosis. The Company is also developing an AAV-based gene therapy program for an undisclosed rare pediatric disease.
MULTERRA BIO, INC. develops a handheld device for performing various diagnostics with a single and consumable cartridge. The company was incorporated in 2015 and is based in San Francisco, California.
Pillo, Inc. designs and develops a digital care management platform that provides health care plans for adults with chronic conditions at home. The company offers Pillo, a robot, which enable people to manage their health; answer health and wellness questions; connect with healthcare professionals; manage vitamins and medication; and store, dispense, and order refills when required. The company’s robot also sends notifications to the user when medications are missed; sees and hears user to keep them healthy and safe; and syncs with wearables and smart home devices. Pillo, Inc. was incorporated in 2015 and is based in New York, New York.